These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28479180)

  • 1. Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®.
    Zhu D; Wu Y; McClellan H; Dai W; Rausch K; Jones D; Aebig J; Barnafo E; Butler B; Lambert L; Narum DL; Duffy PE
    Vaccine; 2017 May; 35(24):3232-3238. PubMed ID: 28479180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.
    Shimp RL; Rowe C; Reiter K; Chen B; Nguyen V; Aebig J; Rausch KM; Kumar K; Wu Y; Jin AJ; Jones DS; Narum DL
    Vaccine; 2013 Jun; 31(28):2954-62. PubMed ID: 23623858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
    Talaat KR; Ellis RD; Hurd J; Hentrich A; Gabriel E; Hynes NA; Rausch KM; Zhu D; Muratova O; Herrera R; Anderson C; Jones D; Aebig J; Brockley S; MacDonald NJ; Wang X; Fay MP; Healy SA; Durbin AP; Narum DL; Wu Y; Duffy PE
    PLoS One; 2016; 11(10):e0163144. PubMed ID: 27749907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.
    Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates.
    Qian F; Wu Y; Muratova O; Zhou H; Dobrescu G; Duggan P; Lynn L; Song G; Zhang Y; Reiter K; MacDonald N; Narum DL; Long CA; Miller LH; Saul A; Mullen GE
    Vaccine; 2007 May; 25(20):3923-33. PubMed ID: 17428587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
    Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
    Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.
    Patra KP; Li F; Carter D; Gregory JA; Baga S; Reed SG; Mayfield SP; Vinetz JM
    Infect Immun; 2015 May; 83(5):1799-808. PubMed ID: 25690099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice.
    Coelho CH; Gazzinelli-Guimaraes PH; Howard J; Barnafo E; Alani NAH; Muratova O; McCormack A; Kelnhofer E; Urban JF; Narum DL; Anderson C; Langhorne J; Nutman TB; Duffy PE
    Vaccine; 2019 Feb; 37(8):1038-1045. PubMed ID: 30685251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial.
    Sagara I; Healy SA; Assadou MH; Kone M; Swihart BJ; Kwan JL; Fintzi J; Sissoko K; Kamate B; Samake Y; Guindo MA; Doucoure M; Niaré K; Dolo A; Diarra B; Rausch KM; Narum DL; Jones DS; MacDonald NJ; Zhu D; Gorres JP; Imeru A; Mohan R; Thera I; Zaidi I; Salazar-Miralles F; Duan J; Neal J; Morrison RD; Muratova O; Sylla D; O'Connell EM; Wu Y; Hume JCC; Coulibaly MB; Anderson CF; Traore SF; Doumbo OK; Duffy PE
    Lancet Infect Dis; 2023 Nov; 23(11):1266-1279. PubMed ID: 37499679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
    Wu Y; Ellis RD; Shaffer D; Fontes E; Malkin EM; Mahanty S; Fay MP; Narum D; Rausch K; Miles AP; Aebig J; Orcutt A; Muratova O; Song G; Lambert L; Zhu D; Miura K; Long C; Saul A; Miller LH; Durbin AP
    PLoS One; 2008 Jul; 3(7):e2636. PubMed ID: 18612426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.
    Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P
    Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.
    Coban C; Ishii KJ; Stowers AW; Keister DB; Klinman DM; Kumar N
    Infect Immun; 2004 Jan; 72(1):584-8. PubMed ID: 14688140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230.
    Scaria PV; Chen BB; Rowe CG; Alani N; Muratova OV; Barnafo EK; Lambert LE; Zaidi IU; Lees A; Rausch KM; Narum DL; Duffy PE
    Vaccine; 2020 Jul; 38(34):5480-5489. PubMed ID: 32600913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant
    Parzych EM; Miura K; Ramanathan A; Long CA; Burns JM
    Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.
    Qian F; Rausch KM; Muratova O; Zhou H; Song G; Diouf A; Lambert L; Narum DL; Wu Y; Saul A; Miller LH; Long CA; Mullen GE
    Vaccine; 2008 May; 26(20):2521-7. PubMed ID: 18423804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.
    Li Y; Leneghan DB; Miura K; Nikolaeva D; Brian IJ; Dicks MD; Fyfe AJ; Zakutansky SE; de Cassan S; Long CA; Draper SJ; Hill AV; Hill F; Biswas S
    Sci Rep; 2016 Jan; 6():18848. PubMed ID: 26743316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.
    MacDonald NJ; Nguyen V; Shimp R; Reiter K; Herrera R; Burkhardt M; Muratova O; Kumar K; Aebig J; Rausch K; Lambert L; Dawson N; Sattabongkot J; Ambroggio X; Duffy PE; Wu Y; Narum DL
    J Biol Chem; 2016 Sep; 291(38):19913-22. PubMed ID: 27432885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding.
    Kumar R; Angov E; Kumar N
    Infect Immun; 2014 Apr; 82(4):1453-9. PubMed ID: 24421036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.